News from the BioRegion STERN

Here you'll find all press releases and news from companies and institutes in the STERN BioRegion.

01/04/2018 | CureVac AG

CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeuti...

Hope in the fight against multi-resistant germs

Researchers from the Universities of Stuttgart and Tübingen prove the effectiveness of new types of antibiotics.

Microalgae Ready for Space

The University of Stuttgart hands over photobioreactor chambers for space experiment on the ISS

Nerve Cells on the ISS: University of Hohenheim Examines How Cells Grow without Gravity

Project NEUROBOX sends human nerve cells to the International Space Stations / Project looks at how nervous systems develop in space / Team accompanies mission with journals How would the first person born in space develop? While it sounds like a question for a science fiction novel, it is the background of a current research project at the Univers...
10/19/2017 | CureVac AG

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

Immuno-oncology collaboration aims to develop up to five cancer vaccines that target neoantigens across multiple tumor types / CureVac to receive an upfront payment of $50 million and an equity investment of €45 million
08/21/2017 | immatics biotechnologies GmbH

Immatics Initiates Personalized Adoptive Cellular Therapy in Patients with Relapsed And/Or Refractory Solid Cancers Using Its Pioneering Target Warehouse

Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its proprietary ACTolog® approach. The IMA1...
08/16/2017 | CureVac AG

Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors

Data validate the strength of CureVac’s RNAntibody® technology to produce high and sustained levels of antibody production in a variety of disease indications

CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine

Data from phase I clinical trial of CureVac’s RNActive® prophylactic vaccine technology in rabies demonstrates for the first time an induction of boostable functional antibodies against a viral antigen when administered via needle-free injection Cu...
07/24/2017 | CureVac AG

CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies

Patent covers Composition of Matter and Methods of Treatment for vaccine/inhibitor combination for the prevention or treatment of cancer and infectious diseases
06/28/2017 | CureVac AG

CureVac Expands GMP Production Capacities for RNA Products

Supply for Full RNA Clinical Pipeline and Later Commercialization Secured CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced during a public open door event at its main location in Tübingen, Germany, on June 24 the extension of its GMP production capabilities to meet the clinical and futur...

Medicxi launches first $300m late-stage life sciences fund Medicxi Growth 1 (MG1), backed by Novartis and Verily

Medicxi announced on June 15th the close of Medicxi Growth 1 (MG1), a new $300 million fund that will focus on growth stage companies in European life sciences.

CeGaT Obtains CLIA Certification, Final Step Towards U.S. Market Entry

CeGaT GmbH, a leading global genetic testing provider focused on large panel and trio-exome diagnostics, has obtained its CLIA certification. After receiving CAP accreditation in 2016, CeGaT has been granted Clinical Laboratory Improvement Amendments (CLIA) certification by The Centers for Medicare & Medicaid Services (CMS), ensuring complian...
06/14/2017 | CureVac AG

CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines

Patents granted for mRNA-based RSV vaccines as well as for vaccination of infants / newborns and elderly with mRNA-based vaccines such as Flu CureVac AG a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has been granted important patents claiming the use of mRNA-based prophylactic vaccines, significantly add...
05/02/2017 | CureVac AG

CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary

CureVac AG, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based therapies, today announced the appointment of Daniel Menichella as CEO of CureVac Inc., its Boston based U.S. subsidiary. Mr. Menichella, an experienced executive in the biotech-industry, will develop CureVac’s US organization with a clear focus on business an...
04/12/2017 | Exyte

M+W Group names new CEO for the Americas Region

Rick Whitney has been named CEO of M+W Group’s Americas Region and President of the company’s subsidiary M+W U.S. Inc. Whitney brings extensive industry expertise to his second stint at M+W Group, where he worked from 1997 to 2014.
04/12/2017 | Curetis GmbH

Curetis erweitert Aufsichtsrat und Medizinischen Beirat

Dr. Nils Clausnitzer für Aufsichtsratsmitgliedschaft nominiert; Dr. Melissa Miller in Medizinischen Beirat aufgenommen
03/29/2017 | Exyte

M+W Group Promotes Smart Lab Design at the Asia Pharma R&D Leaders Summit 2017

M+W Group was invited as a thought leadership company to participate in the Asia Pharma R&D Leaders Summit 2017, a key pharma R&D event in China, being held in Shanghai, China.
03/16/2017 | Exyte

M+W Group on a Successful Streak with Semiconductor Awards

Leading global high-tech engineering company, M+W Group is celebrating their recent successes in semiconductor projects with awards in both China and Taiwan.